This article is more than 5 years old. Information may no longer be current.

Three countries approve Refractec CK device; Lindstrom appointed to board

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

IRVINE, Calif. — Regulatory bodies in Brazil, Russia and Taiwan have granted marketing approval to Refractec Inc. for its ViewPoint CK conductive keratoplasty system, the company announced.

ViewPoint CK is used to improve near vision in patients who have presbyopia. Refractec is seeking expanded U.S. approval for the device to treat refractive error in patients after LASIK, according to a press release from the company.

Refractec also announced the appointment of Richard L. Lindstrom, MD, to its six-member board of directors.